Related Experiment Video

Updated: Aug 19, 2026

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
07:23

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities

Published on: July 29, 2014

Indoprofen, a non-steroidal anti-inflammatory analgesic which does not depress respiration in normal man. A study

A J Love, S H Ripley, J G Brock-Utne

    South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
    |November 23, 1985
    PubMed

    Insights

    Intravenous indoprofen (a non-steroidal anti-inflammatory analgesic) did not affect breathing in healthy volunteers. Morphine, however, showed its typical respiratory depressant effects, highlighting indoprofen

    Area of Science:

    • Pharmacology
    • Respiratory Physiology
    • Pain Management

    Background:

    • Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for analgesia.
    • Opioids like morphine are effective analgesics but carry risks of respiratory depression.
    • Understanding the respiratory safety profile of NSAIDs is crucial for clinical practice.

    Purpose of the Study:

    • To compare the respiratory effects of intravenous indoprofen with morphine.
    • To evaluate the safety of indoprofen regarding respiratory function in healthy subjects.

    Main Methods:

    • Ten healthy volunteers participated in the study.
    • Respiratory parameters were monitored after intravenous administration of indoprofen (400 mg) and morphine (10 mg).

    Main Results:

    • Morphine administration resulted in characteristic adverse respiratory depressant effects.
    • Intravenous indoprofen did not significantly alter the breathing pattern of the volunteers.

    Conclusions:

    • Intravenous indoprofen appears to have a favorable respiratory safety profile compared to morphine.
    • Indoprofen may offer an alternative analgesic option with reduced risk of respiratory compromise.

    More Related Videos

    Development of Recombinant Proteins to Treat Chronic Pain10:37

    Development of Recombinant Proteins to Treat Chronic Pain

    Published on: April 11, 2018

    Intracranial Pharmacotherapy and Pain Assays in Rodents02:26

    Intracranial Pharmacotherapy and Pain Assays in Rodents

    Published on: April 9, 2019

    Related Concept Videos

    Analgesia and Pain Management01:25

    Analgesia and Pain Management

    Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
    Opioid Analgesics: Morphine and Other Natural Cogeners01:20

    Opioid Analgesics: Morphine and Other Natural Cogeners

    Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
    Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

    Opioid Analgesics: Synthetic and Semisynthetic Opioids

    Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
    Parenteral Anesthetics: Overview01:24

    Parenteral Anesthetics: Overview

    Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...